Nodular Prurigo: A Leading Driver Behind Increasing Demand For Targeted Therapies Fueling The Growth Of The Market Due To Their Precision And Improved Patient Outcomes Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Nodular Prurigo Industry Market Size Be by 2025?
In the past few years, the market size of nodular prurigo has seen robust growth. It is projected to expand from $1.17 billion in 2024 to $1.25 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The substantial growth in the historic period can be associated with a rise in dermatological consultations, enhanced awareness among dermatologists, the need for unaddressed medical solutions, a concentration on academic research, and advancements in diagnostic methods.

What's the Long-Term Growth Forecast for the Nodular Prurigo Market Size Through 2029?
In the following years, the market size for nodular prurigo is predicted to experience robust expansion, with projections reaching $1.6 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.4%. The anticipated expansion within the forecast period can be ascribed to factors such as the sanctioning of targeted therapies, increment in research and development funding for rare skin conditions, heightened patient advocacy and awareness initiatives, expansion of health insurance and reimbursements, and advancements in companion diagnostics and biomarkers. Key trends foreseen during this period encompass AI-based diagnostics, gene editing advancements, the use of nanotechnology in drug delivery, innovation in biologics, and the rise of wearable health monitoring devices.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nodular-prurigo-global-market-report

What Are the Key Growth Drivers Fueling the Nodular Prurigo Market Expansion?
Expected growth in the nodular prurigo market can be attributed to the rising need for targeted treatments. Targeted therapies are medical procedures that specifically interfere with the molecular pathways that contribute to the growth and spread of diseases. Their popularity is on the rise due to the precision with which they can treat disorders, their fewer side effects, and their potential to improve patient outcomes when compared to more conventional and less precise therapies. Nodular prurigo fuels the development of targeted treatments due to the existence of a clear unmet medical requirement linked to specific immune pathways like IL-4, IL-13, and IL-31. This, in turn, permits the use of biologics that specifically block these inflammatory signals for a more efficient treatment. For example, NHS England reported in October 2023 that 11 million hormone replacement therapy (HRT) items have been prescribed in England, a 47% rise from 2021-22, with approximately 2.3 million patients receiving prescriptions, representing a year-on-year growth of 29%. Hence, the growing need for targeted treatments bolsters the growth of the nodular prurigo market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24624&type=smp

What Are the Key Trends Driving Nodular Prurigo Market Growth?
Major firms active in the nodular prurigo market are concentrating on obtaining regulatory approvals to broaden their market presence and enhance patient outcomes. Regulatory approvals are the official permission given by government or regulatory authorities for a drug, medical device, or treatment to be marketed and used by the general public. For example, in September 2022, the U.S.-based biotechnology company, Regeneron Pharmaceuticals Inc., gained FDA approval for Dupixent (dupilumab)- the first and exclusive treatment specifically marked for prurigo nodularis in adults. This approval relied on data from two critical Phase 3 trials, PRIME and PRIME2, which showed that Dupixent significantly lessened itch and skin lesions compared to a placebo. Dupixent emerged as the sole medication in the U.S. with an approved indication for the treatment of prurigo nodularis, addressing a significant unmet medical requirement for around 75,000 adults affected by this condition in the U.S.

How Is the Nodular Prurigo Market Segmented?
The nodular prurigo market covered in this report is segmented -

1) By Type: Chronic Nodular Prurigo, Acute Nodular Prurigo, Subacute Nodular Prurigo
2) By Treatment Type: Topical Treatments, Systemic Treatments, Phototherapy, Immunosuppressants
3) By Patient Demographics: Adults, Children, Elderly
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo, Secondary To Dermatologic Conditions, Neuropathic Causes, Systemic Disease-Associated, Psychogenic Prurigo
2) By Acute Nodular Prurigo: Insect Bite-Induced, Allergic Reactions, Drug-Induced Prurigo, Infectious Triggers
3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo, Post-Inflammatory Prurigo, Transient Dermatoses, Reaction To Environmental Irritants

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24624&type=smp

Which Companies Are Leading the Charge in Nodular Prurigo Market Innovation?
Major companies operating in the nodular prurigo market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Galderma S.A., Galderma Laboratories L.P. , Incyte Corporation, Kyowa Kirin Co Ltd., LEO Pharma A/S, Maruho Co Ltd., Kiniksa Pharmaceuticals Ltd., Keymed Biosciences Co Ltd., Trevi Therapeutics Inc., Fierce Pharma, Menlo Therapeutics Inc., VYNE Therapeutics Inc., Celldex Therapeutics Inc.

Which Regions Are Leading the Global Nodular Prurigo Market in Revenue?
North America was the largest region in the nodular prurigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nodular prurigo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report to*day:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24624

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.